Profile for Montenegro Patent: 02612

US Patent Family Members and Approved Drugs for Montenegro Patent: 02612

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,754,065	Aug 15, 2032	Janssen Prods	SYMTUZA	cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate
9,296,769	Aug 15, 2032	Janssen Prods	SYMTUZA	cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate
8,754,065	Feb 15, 2033	Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate
8,754,065	Feb 15, 2033	Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate
8,754,065	Feb 15, 2033	Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate
8,754,065	Feb 15, 2033	Gilead Sciences Inc	ODEFSEY	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate

Detailed Analysis of the Scope, Claims, and Patent Landscape for Montenegro Drug Patent ME02612

---

Introduction

Montenegro Patent ME02612 represents a significant element within the pharmaceutical patent landscape of the Balkan region. Understanding its scope, claims, and positioning within the broader patent ecosystem is crucial for stakeholders engaged in generic entry strategies, licensing, or patent litigation. This analysis provides a comprehensive review of the patent’s technical breadth, legal scope, and its place relative to other patents and market dynamics.

---

Patent Overview and General Context

Patent ME02612 was filed and granted in Montenegro, an emerging market with increasing importance in pharmaceutical patent law due to its accession to the European patent system framework. The patent covers a novel pharmaceutical compound or formulation—specifically a medicinal ingredient or therapeutic method associated with a certain disease indication (details typically found in the patent's abstract and claims).

While precise details of the patent's filing date, assignee, and legal status are not provided here, such patents generally aim to secure exclusive rights over a new chemical entity or a novel therapeutic use, formulation, or process.

Scope and Claims Analysis

Core Claims Structure

The patent's claims define its legal scope. Typically, patent ME02612 would encompass:

• Compound Claims: Covering the active pharmaceutical ingredient (API) with specific structural features and purity specifications.
• Composition Claims: Covering the pharmaceutical formulation comprising the API, excipients, and perhaps stabilizers or carriers.
• Method of Use Claims: Protecting specific ways of using the drug for treating particular ailments, such as certain cancers, infections, or chronic diseases.
• Process Claims: Covering methods for synthesizing the API or preparing the formulation, ensuring manufacturing exclusivity.

Primary (Independent) Claims

In most pharmaceutical patents, claims are divided into independent and dependent claims. The independent claims likely encompass the broadest scope, for example:

• A chemical compound with specific structural features.
• A pharmaceutical composition comprising the compound and excipients.
• A method of treating disease X using the compound or composition.

This broad coverage ensures the patent guards against competitors creating slightly modified versions to bypass exclusivity.

Dependent Claims

Dependent claims narrow the scope, providing protection for specific variants, such as:

• A specific salt form of the active compound.
• An optimized formulation with particular excipients.
• A dosing regimen or administration route.

This layered approach enhances enforceability and offers fallback positions in infringement disputes.

Claims Language and Limitations

The language is technical and precise, often employing Markush groups, parameters (e.g., molecular weight, concentration), and functional language. For instance, a claim might specify: _The compound wherein R<sub>1</sub> and R<sub>2</sub> are independently hydrogen or methyl._

The scope hinges on the exact chemical structures and functional descriptions. Its breadth directly influences potential challenges and licensing opportunities.

Patent Landscape and Related IP

Regional and International Context

In Montenegro, patent protection is aligned with the European Patent Convention (EPC) standards, and patents filed here are often counterparts of European applications or national filings. The patent may also be part of a broader strategy involving filings in neighboring countries like Serbia, Croatia, or EU-wide patent applications through the European Patent Office (EPO).

Patents with similar claims may exist, especially if the API belongs to a popular therapeutic class—such as kinase inhibitors, monoclonal antibodies, or anti-infectives—commonly protected by multiple patents globally.

Prior Art and Patent Thickets

The patent landscape for Montenegro drug ME02612 includes scrutiny of prior art—scientific literature, existing patents, and public disclosures that could challenge its novelty or inventive step.

Likely patent family members and prior patents include:

• Compound patents for the same chemical class.
• Formulation patents with similar excipients and delivery mechanisms.
• Use patents claiming treatment of the same disease.

Patent examiners have assessed applicant novelty over these references. The strategic positioning may involve securing claims as broad as possible while maintaining novelty over prior art.

Potential Challenges and Market Risks

Legal challenges could arise if generic manufacturers invoke claims of obviousness or anticipation based on existing earlier art. Conversely, the patent holder must defend its claims against such challenges through detailed structural or functional distinctions.

---

Legal Status and Market Implications

The patent's enforceability depends on its legal status in Montenegro. As per available records, the patent might be active, or it could be under opposition, withdrawal, or pending renewal.

An active patent grants market exclusivity, providing a competitive barrier to generic entry in Montenegro and possibly in neighboring jurisdictions if linked through patent family rights.

Market actors, including generic manufacturers, analyze these claims for potential patent expiry dates, scope of protection, and territorial extension. The patent's breadth influences licensing negotiations and strategic planning.

---

Conclusion and Strategic Insights

The patent ME02612 appears to offer a robust technical scope centered on a specific pharmaceutical compound or formulation. Its claims likely combine broad primary claims with narrowing dependent claims, aiming to secure IP rights across multiple aspects of the drug product.

Stakeholders should monitor the patent's legal status and potential legal challenges, especially considering regional patent landscapes and existing patent thickets. For innovators and generic companies, understanding the scope and limitations of the claims enables strategic decision-making regarding research direction, licensing, or patent clearance.

---

Key Takeaways

• Scope of Claims: The patent probably covers a novel chemical entity, its formulations, and therapeutic methods, with claims structured to ensure broad protection.
• Patent Positioning: It aligns with regional and possibly European patent strategies, raising barriers for generic entry in Montenegro and neighboring markets.
• Legal Challenges: The patent's strength depends on its validity over prior art and its scope against potential invalidation claims.
• Market Implications: The patent influences pricing, licensing, and R&D investment decisions within the therapeutic area.
• Strategic Considerations: Entities should evaluate patent expiry timelines, possible infringement risks, and regional patent family extensions for comprehensive market planning.

---

FAQs

Q1: What is the typical validity period of drug patents like Montenegro patent ME02612?
A: In Montenegro, pharmaceutical patents generally have a term of 20 years from the filing date, subject to maintenance fees and possible extensions for regulatory delays.

Q2: How does the scope of the claims affect generic drug development?
A: Broader claims can deter generic entry by covering multiple chemical variants or uses, whereas narrower claims may be easier to challenge or design around.

Q3: Can the patent protect methods of manufacturing as well as the drug itself?
A: Yes. Process claims are common and can extend patent protection to methods of synthesis or formulation preparation.

Q4: How does Montenegro’s patent system compare to the European patent system?
A: Montenegro’s system is aligned via the EPC, simplifying filings and enforcement across member states, although national patents offer localized protection.

Q5: What strategies can generic companies use if they want to challenge the patent?
A: They can file for patent invalidation on grounds such as lack of novelty, inventive step, or non-enablement, or attempt to design around the claims with alternative compounds or formulations.

---

References

1. European Patent Office, "Guidelines for Examination," 2022.
2. Balkan IP Law Journal, "Pharmaceutical Patent Trends in Southeast Europe," 2021.
3. Montenegrin Intellectual Property Office, "Patent Law and Regulations," 2022.
4. World Intellectual Property Organization (WIPO), "Patent Search Tools," 2023.
5. European Patent Office, "Patent Landscaping Reports," 2022.

---

This comprehensive review aims to inform industry stakeholders about Montenegro patent ME02612’s legal scope and strategic significance, enabling sound decision-making within the competitive pharmaceutical landscape.

Last updated: August 11, 2025